Targeting tumors with LIGHT to generate metastasis-clearing immunity

Cytokine and Growth Factor Reviews

Volumn 19, Issue 3-4, 2008, Pages 285-294

  Yu, Ping ^a   Fu, Yang Xin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Gene therapy; Immunotherapy; Metastasis; T cells; TNF superfamily; Tumor

Indexed keywords

HERPESVIRUS ENTRY MEDIATOR LIGAND; LYMPHOTOXIN BETA RECEPTOR; PROTEIN LIGHT; TUMOR NECROSIS FACTOR;

ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; STROMA CELL; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NEOPLASM METASTASIS; NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 49949152063     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2008.04.004     Document Type: Article

References (100)

1. Boon T., and van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 183 (1996) 725-729
2. Mauri D.N., Ebner R., Montgomery R.I., Kochel K.D., Cheung T.C., Yu G.L., et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 8 (1998) 21-30
3. Tamada K., Shimozaki K., Chapoval A.I., Zhu G., Sica G., Flies D., et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 6 (2000) 283-289
4. Rooney I.A., Butrovich K.D., Glass A.A., Borboroglu S., Benedict C.A., Whitbeck J.C., et al. The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem 275 (2000) 14307-14315
5. Harrop J.A., McDonnell P.C., Brigham-Burke M., Lyn S.D., Minton J., Tan K.B., et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 273 (1998) 27548-27556
6. Kwon B.S., Tan K.B., Ni J., Oh K.O., Lee Z.H., Kim K.K., et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 272 (1997) 14272-14276
7. Murphy M., Walter B.N., Pike-Nobile L., Fanger N.A., Guyre P.M., Browning J.L., et al. Expression of the lymphotoxin beta receptor on follicular stromal cells in human lymphoid tissues. Cell Death Differ 5 (1998) 497-505
8. Browning J.L., Sizing I.D., Lawton P., Bourdon P.R., Rennert P.D., Majeau G.R., et al. Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. J Immunol 159 (1997) 3288-3298
9. Woglom W.H. Immunity to transplantable tumors. Cancer Rev 4 (1929) 129-214
10. Singh S., Ross S.R., Acena M., Rowley D.A., and Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 175 (1992) 139-146
11. Ochsenbein A.F., Klenerman P., Karrer U., Ludewig B., Pericin M., Hengartner H., et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96 (1999) 2233-2238
12. Willimsky G., and Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437 (2005) 141-146
13. Ganss R., Limmer A., Sacher T., Arnold B., and Hammerling G.J. Autoaggression and tumor rejection: it takes more than self-specific T-cell activation. Immunol Rev 169 (1999) 263-272
14. Wick M., Dubey P., Koeppen H., Siegel C.T., Fields P.E., Fitch F.W., et al. Antigenic cancer cells can grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 186 (1997) 229-237
15. Bai X.F., Gao J.X., Liu J., Wen J., Zheng P., and Liu Y. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen. Cancer Res 61 (2001) 6860-6867
16. Spiotto M.T., Yu P., Rowley D.A., Nishimura M.I., Meredith S.C., Gajewski T.F., et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17 (2002) 737-747
17. Ochsenbein A.F., Sierro S., Odermatt B., Pericin M., Karrer U., Hermans J., et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411 (2001) 1058-1064
18. Juprelle-Soret M., Wattiaux-De Coninck S., and Wattiaux R. Subcellular localization of transglutaminase. Effect of collagen. Biochem J 250 (1988) 421-427
19. Savinov A.Y., Wong F.S., Stonebraker A.C., and Chervonsky A.V. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. J Exp Med 197 (2003) 643-656
20. Schreiber H. Tumor immunology. In: Paul W.E. (Ed). Fundamental immunology. 5th ed. (2003), Lippincott-Raven Publishers, Philadelphia
21. Anderson M.S., Venanzi E.S., Klein L., Chen Z., Berzins S.P., Turley S.J., et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 298 (2002) 1395-1401
22. Lee Y., Chin R.K., Christiansen P., Sun Y., Tumanov A.V., Wang J., et al. Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity 25 3 (2006) 499-509
23. Aloisi F., and Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6 (2006) 205-217
24. Ruddle N.H. Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development. Immunol Res 19 (1999) 119-125
25. Fu Y.X., and Chaplin D.D. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 17 (1999) 399-433
26. Futterer A., Mink K., Luz A., Kosco-Vilbois M.H., and Pfeffer K. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 9 (1998) 59-70
27. Matsumoto M., Mariathasan S., Nahm M.H., Baranyay F., Peschon J.J., and Chaplin D.D. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers. Science 271 (1996) 1289-1291
28. Rennert P.D., James D., Mackay F., Browning J.L., and Hochman P.S. Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity 9 (1998) 71-79
29. Ngo V.N., Korner H., Gunn M.D., Schmidt K.N., Riminton D.S., Cooper M.D., et al. Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med 189 (1999) 403-412
30. Cuff C.A., Schwartz J., Bergman C.M., Russell K.S., Bender J.R., and Ruddle N.H. Lymphotoxin alpha3 induces chemokines and adhesion molecules: insight into the role of LT alpha in inflammation and lymphoid organ development. J Immunol 161 (1998) 6853-6860
31. Drayton D.L., Ying X., Lee J., Lesslauer W., and Ruddle N.H. Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. J Exp Med 197 (2003) 1153-1163
32. Hjelmstrom P., Fjell J., Nakagawa T., Sacca R., Cuff C.A., and Ruddle N.H. Lymphoid tissue homing chemokines are expressed in chronic inflammation. Am J Pathol 156 (2000) 1133-1138
33. Kratz A., Campos-Neto A., Hanson M.S., and Ruddle N.H. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 183 (1996) 1461-1472
34. Spriggs D.R., Sherman M.L., Michie H., Arthur K.A., Imamura K., Wilmore D., et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 80 (1988) 1039-1044
35. Schrama D., thor Straten P., Fischer W.H., McLellan A.D., Brocker E.B., Reisfeld R.A., et al. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 14 (2001) 111-121
36. Cyster J.G. Chemokines and cell migration in secondary lymphoid organs. Science 286 (1999) 2098-2102
37. Kirk C.J., Hartigan-O'Connor D., Nickoloff B.J., Chamberlain J.S., Giedlin M., Aukerman L., et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 61 (2001) 2062-2070
38. Wang J., Foster A., Chin R., Yu P., Sun Y., Wang Y., et al. The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function. Eur J Immunol 32 (2002) 1969-1979
39. Wang J., Lo J.C., Foster A., Yu P., Chen H.M., Wang Y., et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J Clin Invest 108 (2001) 1771-1780
40. Yu P., Lee Y., Liu W., Chin R.K., Wang J., Wang Y., et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5 (2004) 141-149
41. Sharma S., Stolina M., Luo J., Strieter R.M., Burdick M., Zhu L.X., et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 164 (2000) 4558-4563
42. Wolkers M.C., Brouwenstijn N., Bakker A.H., Toebes M., and Schumacher T.N. Antigen bias in T cell cross-priming. Science 304 (2004) 1314-1317
43. Yu P., Spiotto M.T., Lee Y., Schreiber H., and Fu Y.X. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med 197 (2003) 985-995
44. Chen L. Overcoming T cell ignorance by providing costimulation. Implications for the immune response against cancer. Adv Exp Med Biol 451 (1998) 159-165
45. Lenschow D.J., Walunas T.L., and Bluestone J.A. CD28/B7 system of T cell costimulation. Annu Rev Immunol 14 (1996) 233-258
46. Pardoll D.M. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2 (2002) 227-238
47. Mortarini R., Scarito A., Nonaka D., Zanon M., Bersani I., Montaldi E., et al. Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles. Cancer Res 65 (2005) 3428-3436
48. Wu Q., Wang Y., Wang J., Hedgeman E.O., Browning J.L., and Fu Y.X. The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissues. J Exp Med 190 (1999) 629-638
49. Lanzavecchia A., and Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 106 (2001) 263-266
50. Liu Y.J. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106 (2001) 259-262
51. Mellman I., and Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106 (2001) 255-258
52. Randolph G.J., Sanchez-Schmitz G., and Angeli V. Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances. Springer Semin Immunopathol 26 (2005) 273-287
53. Sozzani S., Allavena P., Vecchi A., and Mantovani A. Chemokines and dendritic cell traffic. J Clin Immunol 20 (2000) 151-160
54. Kabashima K., Banks T.A., Ansel K.M., Lu T.T., Ware C.F., and Cyster J.G. Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 22 (2005) 439-450
55. Wang Y.G., Kim K.D., Wang J., Yu P., and Fu Y.X. Stimulating lymphotoxin {beta} receptor on the dendritic cells is critical for their homeostasis and expansion. J Immunol 175 (2005) 6997-7002
56. Inaba K., Schuler G., Witmer M.D., Valinksy J., Atassi B., and Steinman R.M. Immunologic properties of purified epidermal Langerhans cells. Distinct requirements for stimulation of unprimed and sensitized T lymphocytes. J Exp Med 164 (1986) 605-613
57. Labeur M.S., Roters B., Pers B., Mehling A., Luger T.A., Schwarz T., et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 162 (1999) 168-175
58. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194 (2001) 769-779
59. Ohlen C., Kalos M., Cheng L.E., Shur A.C., Hong D.J., Carson B.D., et al. CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J Exp Med 195 (2002) 1407-1418
60. Dhodapkar M.V., Steinman R.M., Sapp M., Desai H., Fossella C., Krasovsky J., et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104 (1999) 173-180
61. Probst H.C., Lagnel J., Kollias G., and van den Broek M. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity 18 (2003) 713-720
62. Schuler G., and Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186 (1997) 1183-1187
63. Summers-DeLuca L.E., McCarthy D.D., Cosovic B., Ward L.A., Lo C.C., Scheu S., et al. Expression of lymphotoxin-alphabeta on antigen-specific T cells is required for DC function. J Exp Med 204 (2007) 1071-1081
64. Morel Y., Truneh A., Sweet R.W., Olive D., and Costello R.T. The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J Immunol 167 (2001) 2479-2486
65. Nowak A.K., Lake R.A., Marzo A.L., Scott B., Heath W.R., Collins E.J., et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170 (2003) 4905-4913
66. Zhang B., Bowerman N.A., Salama J.K., Schmidt H., Spiotto M.T., Schietinger A., et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 204 (2007) 49-55
67. Browning J.L., Miatkowski K., Sizing I., Griffiths D., Zafari M., Benjamin C.D., et al. Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. J Exp Med 183 (1996) 867-878
68. Zhai Y., Guo R., Hsu T.L., Yu G.L., Ni J., Kwon B.S., et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 102 (1998) 1142-1151
69. Yu P., Lee Y., Wang Y., Liu X., Auh S., Gajewski T.F., et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 179 (2007) 1960-1968
70. Clark Jr. W.H., Elder D.E., Guerry D., Braitman L.E., Trock B.J., Schultz D., et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81 (1989) 1893-1904
71. Clemente C.G., Mihm Jr. M.C., Bufalino R., Zurrida S., Collini P., and Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 (1996) 1303-1310
72. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
73. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348 (2003) 203-213
74. Bhowmick N.A., Neilson E.G., and Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 432 (2004) 332-337
75. Yu P., Rowley D.A., Fu Y.X., and Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 18 (2006) 226-231
76. Torre-Amione G., Beauchamp R.D., Koeppen H., Park B.H., Schreiber H., Moses H.L., et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87 (1990) 1486-1490
77. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198 (2003) 1875-1886
78. Huber S., Schramm C., Lehr H.A., Mann A., Schmitt S., Becker C., et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 173 (2004) 6526-6531
79. Ahmadzadeh M., and Rosenberg S.A. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 174 (2005) 5215-5223
80. Zhang Q., Yang X., Pins M., Javonovic B., Kuzel T., Kim S.J., et al. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res 65 (2005) 1761-1769
81. Yu P., Lee Y., Liu W., Krausz T., Chong A., Schreiber H., et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201 (2005) 779-791
82. Mempel T.R., Pittet M.J., Khazaie K., Weninger W., Weissleder R., von Boehmer H., et al. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 25 (2006) 129-141
83. Harrop J.A., Reddy M., Dede K., Brigham-Burke M., Lyn S., Tan K.B., et al. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines. J Immunol 161 (1998) 1786-1794
84. Liu J., Schmidt C.S., Zhao F., Okragly A.J., Glasebrook A., Fox N., et al. LIGHT-deficiency impairs CD8+ T cell expansion, but not effector function. Int Immunol 15 (2003) 861-870
85. Scheu S., Alferink J., Potzel T., Barchet W., Kalinke U., and Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med 195 (2002) 1613-1624
86. Tamada K., Ni J., Zhu G., Fiscella M., Teng B., van Deursen J.M., et al. Cutting edge: selective impairment of CD8+ T cell function in mice lacking the TNF superfamily member LIGHT. J Immunol 168 (2002) 4832-4835
87. Fan Z., Yu P., Wang Y., Wang Y., Fu M.L., Liu W., et al. NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood 107 (2006) 1342-1351
88. Shaikh R.B., Santee S., Granger S.W., Butrovich K., Cheung T., Kronenberg M., et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol 167 (2001) 6330-6337
89. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909-915
90. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest 21 (2003) 873-886
91. Stift A., Friedl J., Dubsky P., Bachleitner-Hofmann T., Schueller G., Zontsich T., et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol 21 (2003) 135-142
92. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190 (1999) 1669-1678
93. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198 (2003) 569-580
94. Dudley M.E., Wunderlich J., Nishimura M.I., Yu D., Yang J.C., Topalian S.L., et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24 (2001) 363-373
95. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
96. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3 (2003) 453-458
97. Miller F.R., Miller B.E., and Heppner G.H. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3 (1983) 22-31
98. Parviz M., Chin C.S., Graham L.J., Miller C., Lee C., George K., et al. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol Immunother 52 (2003) 739-750
99. Pulaski B.A., and Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58 (1998) 1486-1493
100. Loeffler M., Le'Negrate G., Krajewska M., and Reed J.C. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci USA 104 (2007) 12879-12883